Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5091040
Max Phase: Preclinical
Molecular Formula: C69H85FN10O12S2
Molecular Weight: 1329.63
Molecule Type: Unknown
Associated Items:
ID: ALA5091040
Max Phase: Preclinical
Molecular Formula: C69H85FN10O12S2
Molecular Weight: 1329.63
Molecule Type: Unknown
Associated Items:
Canonical SMILES: COc1ccc(C[C@@H]2NC(=O)[C@H]([C@@H](C)OC)NC(=O)[C@@H]3[C@@H]4CCN3C(=O)[C@H](Cc3c[nH]c5ccc(F)cc35)NC(=O)[C@H](Cc3cccc(c3)C/C=C/CO4)NC(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)CCSCc3cccc(c3)CSCCNC(=O)[C@]3(C)CCCN3C2=O)cc1
Standard InChI: InChI=1S/C69H85FN10O12S2/c1-41-61(82)74-42(2)62(83)75-54-35-46-14-9-13-44(32-46)12-7-8-29-92-57-23-28-79(66(87)56(76-63(54)84)36-49-38-72-53-22-19-50(70)37-52(49)53)60(57)65(86)78-59(43(3)90-5)64(85)77-55(34-45-17-20-51(91-6)21-18-45)67(88)80-27-11-25-69(80,4)68(89)71-26-31-94-40-48-16-10-15-47(33-48)39-93-30-24-58(81)73-41/h7-10,13-22,32-33,37-38,41-43,54-57,59-60,72H,11-12,23-31,34-36,39-40H2,1-6H3,(H,71,89)(H,73,81)(H,74,82)(H,75,83)(H,76,84)(H,77,85)(H,78,86)/b8-7+/t41-,42+,43+,54-,55-,56-,57-,59-,60-,69-/m0/s1
Standard InChI Key: CETIBYSEEVJRNF-KCUILIDKSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1329.63 | Molecular Weight (Monoisotopic): 1328.5774 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Tucker TJ, Embrey MW, Alleyne C, Amin RP, Bass A, Bhatt B, Bianchi E, Branca D, Bueters T, Buist N, Ha SN, Hafey M, He H, Higgins J, Johns DG, Kerekes AD, Koeplinger KA, Kuethe JT, Li N, Murphy B, Orth P, Salowe S, Shahripour A, Tracy R, Wang W, Wu C, Xiong Y, Zokian HJ, Wood HB, Walji A.. (2021) A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors., 64 (22.0): [PMID:34704436] [10.1021/acs.jmedchem.1c01599] |
Source(1):